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Glucose metabolism via sorbitol pathway
has been implicated as a possible contributor to
the diabetes-related vascular changes. Nitric
oxide plays a major regulatory role in the vas-
cular dilatatory and constricted response. Also
it has been observed that diabetes causes vascu-
lar changes leading to a decrease in nitric oxide
production. Additionally the accumulation of
sorbitol is also related to decreased nitric oxide
production. In the present study we investigat-
ed the effect of normal and high glucose in the
presence or absence of both interleukin-1β β or
an aldose reductase inhibitor on nitric oxide
production in rat aortic rings in vitro. Aortic
rings from normal male Wistar rats were dis-
sected and incubated for 24 to 48 hrs in the
presence of glucose (5.0 mM or 20 mM) or
with or without interleukin (20 ng/ml). Other
rings were incubated in the above media with
the addition of the aldose reductase inhibitor
(WAY 121509). Interleukin-1β stimulated the
24 hr nitric oxide production and WAY 121509
decreased it under both low and high glucose
culture conditions. The interleukin-1β stimula-
tion was continued for 72 hrs. Nitric oxide pro-
duction in response to interleukin-1β was
greater at all time points when compared to the
incubation in media without interleukin-1β. In
media containing WAY 121509 the nitric oxide
production was decreased. Interleukin-1β stim-
ulated a greater increase in nitric oxide produc-
tion from aortic rings when incubated in high
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1560-4284/02 $12.00 + .00glucose when compared to normal glucose. The
inhibitory effect of aldose reductase inhibition
was reversible after 24 hr inhibition under both
normal and high glucose conditions. We con-
clude that high glucose enhances the inter-
leukin-1β-induced nitric oxide synthesis and
the cytokine-induced nitric oxide production
was inhibited by aldose reductase inhibition.
Nitric oxide production may be linked to redox
influences caused by the polyol pathway.
INTRODUCTION
The diversion of glucose into the sorbitol
pathway has been extensively studied as one of
the possible mechanisms leading to diabetes-
associated-disease in the eyes, kidneys, nerves,
and blood vessels [1-3]. Specific aspects of the
sorbitol pathway producing physiological
changes that might lead to dysfunction include
the accumulation of polyols, inositol depletion,
NADPH depletion, and oxidative stress, which
alter osmolarity, signal transduction, activity of
NADPH-dependent enzymes, and cell bio-
chemistry [4, 5]. This augmentation of the sor-
bitol pathway has been demonstrated particu-
larly in blood vessels and vascular cells [6, 7].
Nitric oxide synthesis and activity plays a
major regulatory role in the regulation of vas-
cular dilation and contraction. The dysfunction
of nitric oxide synthase and/or decrease in the
nitric oxide production system has also been
suggested as a major physiological alteration in
diabetes [8-10].
Many studies have investigated the effects of
inhibiting aldose reductase on the pathologies
of diabetes [11-13]. In animal models, aldose
reductase inhibitors (ARIs) have been effective
in preventing the pathology (nephropathy, neu-
ropathy and retinopathy) associated with
experimental diabetes [12-14]. Furthermore,
ARIs have been shown to reduce some of the
biochemical markers (polyol accumulation,
inositol depletion) associated with diabetes in
cell culture systems [15-18]. One interesting
aspect of the ARI effect is that they are most
effective at reducing pathology during the onset
of diabetes but seem less effective in reversing
the pathology and its progression after it has
been induced [19-22].
Several reports indicate that ARIs can be
used to test, in part, the hypothesis that the sor-
bitol pathway mediates effects of high glucose
on isolated tissues [16, 22]. There are also
reports that metabolism through the sorbitol
pathway leads to a decrease in nitric oxide syn-
thase due to the depletion of NADPH [23]. In
this study we investigated the effects of aldose
reductase inhibition (ARI WAY 121509) on
interleukin-1β-induced increased nitric oxide
synthesis in rat aortic rings in the presence of
low and high glucose concentrations.
MATERIALS AND METHODS
Normal male Wistar rats (Harlan
Laboratories) were used. Animals were main-
tained on standard laboratory chow and water.
The protocol for the study was approved by the
Animal Investigation Committee. The rats were
killed by decapitation and aortic rings were dis-
sected and incubated for 24 h in minimal essen-
tial media containing glucose 5.0 mM (NG) or
glucose containing 20 mM (HG). Other media
contained NG plus interleukin (20 ng/ml; NG-
IL) or high glucose plus interleukin (20 ng/ml;
HL-IL). In addition, other rings were incubated
in the above media plus 0.05% dimethylsulfox-
ide (0.05% DMSO, vehicle) or 100 mg/ml of
the aldose reductase inhibitor, WAY 121509.
The concentration of WAY 121509 used in
these experiments was calculated based on the
range of concentrations found in plasma of dia-
betic or galactosemic animals treated with this
drug [24-27].
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In other experiments, rat aortic rings were
incubated in the different media as described
above, but were maintained for three periods of
24 h. Every 24 h the cell media were replaced
with media identical to the treatment in which
the aortic rings had been incubated. The objec-
tive of this experiment was to study the time
course of NO synthesis by aortic rings in each
of the treatments when maintained the same
after 24 h media, with replacement during the
72 h paradigm. The data collected provides a
baseline for comparison of the effects of replac-
ing media with non-identical treatments after
the initial 24 h period.
In the same experiments, some rings were
selected for studying the effect of replacement
with media containing 0.05% DMSO/inter-
leukin-1β or media containing 100 mg/ml WAY
121509 plus interleukin-1β and viceversa after
the initial 24 h period. These experiments eval-
uated the effect of WAY 121509 on NO syn-
thesis already induced by interleukin-1β in aor-
tic rings incubated with normal and high glu-
cose media. In addition, these experiments
determined whether removal of WAY 121509
after the initial 24 h period had long lasting
effects on NO synthesis.
NO ANALYSIS
The NO synthesis measurements were ana-
lyzed via enzymatic/Griess reaction method.
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FIGURE 1
Effect of WAY 121509 (100 mg/ml) on the interleukin-1β-stimulated NO production in rat aortic rings incubated for 24 h under nor-
mal and high glucose conditions. Open bars: defined as control treatments (NG, HG, NGIL, and HGIL).  Filled bars: rings in the same
four treatments plus the addition of the vehicle 0.05% DMSO. Cross-hatch bars: same four treatments plus the aldose reductase
inhibitor WAY 121509 and 0.05% DMSO. NO estimation was performed via nitrite/nitrate measurement by the enzymatic/Griess reac-
tion method. ANOVA repeated measures (Student-Newman-Keuls Method), p<0.001. Different vowels represent statistical difference
among groups at p<0.05. N= 6 animals.14 MORALES, ET AL.
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FIGURE 2
A 72 h study showing the time course for NO synthesis in twelve different groups of rat aortic rings. Panel A: Aortic rings incubated in
interleukin-1β-free treatments (NG, HG, NGD, HGD, NGW, and HGW); Panel B: Aortic rings incubated in normal glucose media con-
taining interleukin-1β only or in combination with either vehicle (0.05% DMSO) or 100 mg/ml WAY 121509; Panel C: Aortic rings incu-
bated in high glucose media containing interleukin-1β only or in combination with either vehicle (0.05% DMSO) or 100 mg/ml WAY
121509. ANOVA repeated measures (Student-Newman-Keuls Method), p<0.001; *, NGILD versus NGILW at all time points and
NGILD and NGIL versus treatments in Panel A, p<0.05; **, HGILD and HGIL versus HGILW at all time points, HGILD and HGIL ver-
sus treatments in Panels A and B at all time points, p<0.05. N= 6 animals.Data was analyzed using ANOVA with repeat-
ed measures with post-hoc analysis using
Student-Newman-Keuls.
RESULTS
Aortic rings incubated with 5 mM (NG) and
20 mM (HG) glucose in interleukin-1β-free
media contained similar nitrate/nitrite levels
compared to rings in identical media containing
100 mg/ml WAY 121509 or vehicle (0.05%
DMSO). Interleukin-1β significantly induced
nitric oxide (NO) production and WAY
121509 (100 mg/ml) attenuated by 60% this
response in aortic rings incubated for 24 h with
either normal or high glucose media (Figure 1).
Vehicle (0.05% DMSO) did not interfere with
the interleukin-1β-induced NO production. 
The multi-day experiments, in which the
media were replaced every 24 h but the same
treatment was present for 72 hr, confirmed a 24
hr stimulation that was continued for 72 hr
(Figure 2). These experiments further demon-
strated that for the treatments that induced an
increase in NO synthesis, the synthesis of NO
increased linearly from day to day. Treatments
containing interleukin-1β in the absence of
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FIGURE 3
Effect of WAY 121509 (100 mg/ml) on the interleukin-1β-induced NO synthesis in rat aortic rings during 48 h incubations under high
glucose conditions. Media was sampled and replaced at the end of 24 h and sampled at the end of the next 24 h (time point= 48 h).
Solid lines represent periods during which rings were incubated in the presence of 0.05% DMSO. Dashed lines represent periods dur-
ing which rings were incubated in the presence of WAY 121509 in 0.05% DMSO. Curve 1: rings treated with HGIL containing 0.05%
DMSO during the first 24 h incubation period and replaced with identical treatment for the second 24 h. Curve 2: rings treated with
HGIL containing 0.05% DMSO during the initial 24 h period and replaced with HGIL containing 100 mg/ml WAY 121509 during the
second 24 h. Curve 3: rings treated with HGIL containing 100 mg/ml WAY 121509 during the first 24 h incubation period and replaced
with identical treatment for the second 24 h. Curve 4: rings treated with HGIL containing 100 mg/ml WAY 121509 during the initial
24 h period and replaced with HGIL media containing 0.05% DMSO during the last 24 h period. ANOVA repeated measures (Student-
Newman-Keuls Method), p<0.001; *, incubation sequence (1, 2) versus (3, 4) at 24 h; and **, incubation sequence (3) versus (1, 2, and
4) at 48 hr, p<0.05. N= 6 animals.WAY 121509 exhibited significantly more NO
synthesis at all time points compared to media
without interleukin-1β and media containing
WAY 121509. Aortic rings in high glucose
media containing interleukin-1β had a 3-5 fold
increase in nitrate/nitrite accumulation com-
pared to normal glucose and interleukin-1β
treatment at all time points studied. All groups
incubated in interleukin-1β-free media showed
no significant differences in NO production. In
the presence of high glucose, WAY 121509
caused a significant inhibition (p<0.001) of
interleukin-1β induction of NO synthesis.
Similarly, WAY 121509 reduced interleukin-1β-
induced NO synthesis in normal glucose media. 
In the next study we compared the efficacy
of WAY 121509 on blocking the effect of HGIL
to its capability to reverse an already estab-
lished effect of HGIL (Figure 3). To make this
comparison, aortic rings were incubated in high
glucose media containing interleukin-1β, with
or without WAY 121509 present, during the
first 24 hr, followed by GHIL with or without
WAY 121509 during the second 24 hr. The
vehicle, 0.05% DMSO was present when WAY
121509 was not. The presence of WAY 121509
during the first 24 h period and throughout the
48 h period caused an inhibitory effect on the
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FIGURE 4
Effect of WAY 121509 (100 mg/ml) on the interleukin-1β-induced NO synthesis in rat aortic rings during 48 h incubations under nor-
mal glucose conditions. Media was sampled and replaced at the end of 24 hr and sampled at the end of the next 24 hr (time point= 48
h). Solid lines represent periods during which rings were incubated in the presence of 0.05% DMSO. Dashed lines represent periods
during which rings were incubated in the presence of WAY 121509 in 0.05% DMSO.  Curve 1: rings treated with NGIL containing
0.05% DMSO during the first 24 h incubation period and replaced with identical treatment for the second 24 h. Curve 2: rings treat-
ed with NGIL containing 0.05% DMSO during the first 24 h period and replaced with NGIL containing 100 mg/ml WAY 121509 dur-
ing the second 24 h. Curve 3: rings treated with NGIL containing 100 mg/ml WAY 121509 during the first 24 h incubation period and
replaced with identical treatment for the second 24 h. Curve 4: rings treated with NGIL containing 100 mg/ml of WAY 121509 during
the initial 24 h period only and replaced with media containing 0.05% DMSO during the last 24 h period. ANOVA repeated measures
(Student-Newman-Keuls Method), p<0.001; *, incubation sequences (1, 2) versus (3, 4) at 24 h; and **, incubation sequences (1, 4)
versus (2, 3) at 48 hr, p<0.05. N= 6 animals.interleukin-1β-stimulated NO synthesis. When
aortic rings were incubated first in HGIL, the
synthesis of NO continued to increase during
the second 24 h. Replacement of HGIL media
with HGILW after the first 24 h period result-
ed in a further 1.68-fold increase in
nitrate/nitrite accumulation during the second
24 h period, this was not significantly different
from NO levels measured for rings in HGILD
throughout the 48 h. Aortic rings incubated in
HGILW during the first 24 h and then incubat-
ed with HGILD during the second 24 h period
demonstrated an increase in nitrite/nitrate
accumulation. This was comparable to rings
incubated in HGILD during both 24 h periods. 
Rings incubated in the presence of inter-
leukin-1β in normal media with or without
WAY 121509 were studied (Figure 4). Aortic
rings incubated with NGIL in the presence of
WAY 121509 during the first 24 hr period and
throughout the 48 hr period exhibited a signif-
icant reduction in nitrate/nitrite accumulation.
Rings incubated in NGIL for the second 24 hr
period with previous treatment in NGILW for
the initial 24 hr period recovered the ability to
synthesize NO to the same levels as rings in
NGIL throughout 48 hr. Thus, the inhibitory
effect of WAY 121509 applied before the
induction of NO synthesis by interleukin-1β
under high glucose conditions was not
observed if WAY 121509 was applied after the
induction of NOS had already occurred.
Furthermore, the effect of WAY 121509 was
reversible since its removal from the incubation
media restored the interleukin-1β-induced NO
synthesis to values similar to rings that had not
been exposed at all the aldose reductase
inhibitor.
DISCUSSION
This is the first demonstration that an aldose
reductase inhibitor (WAY 121509) antagonizes
NO synthesis induced by a potent cytokine
such as interleukin-1β.  This antagonism was
maintained for as long as WAY 121509 was
present, regardless of whether the aortic rings
were incubated in normal or high glucose con-
ditions. Removal of WAY 121509 completely
restored the NO synthesis to control levels,
indicating its reversibility. Interestingly, in high
glucose conditions, WAY 121509 was effective
in inhibiting NO synthesis only when applied
prior to NOS induction. Exposure of aortic
rings to WAY 121509 after NOS induction
effectively inhibited NO synthesis only under
normal glucose conditions but failed under
high glucose conditions, suggesting that high
glucose-elicited changes in aortic rings sup-
pressed the effect of WAY 121509 on NO syn-
thesis.
These results in high glucose media showed a
similar pattern to previous observations in dia-
betic and galactosemic (exaggerates the polyol
pathway) animal models treated with aldose
reductase inhibitors at different glycemic stages
[28]. Administration of aldose reductase
inhibitor at the onset of clinical diabetes [29] or
experimental diabetes [25, 30] and galac-
tosemia [3], results in the prevention of pathol-
ogy-associated with excessive glucose metabo-
lism by the polyol pathway probably due to the
absence of chronic hyperglycemia. On the other
hand, administration of aldose reductase
inhibitors late in experimental diabetes or
galactosemia was less effective at reducing
pathology-associated with polyol pathway
hyperactivity [28]. Thus, in both of these in
vivo models and our in vitro high glucose
model the early presence of WAY 121509 was
necessary to block the hyperglycemic, diabetic,
or galactosemic effect.
In experiments with rats and dogs, the effi-
cacy of aldose reductase inhibitors at reducing
polyol related pathology decreased as the con-
dition progressed without intervention therapy
[25]. In these studies of diabetic as well as
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particular trial depended on whether the aldose
reductase inhibitor was administered at the
onset, early or late in experimental diabetes or
galactosemia. 
WAY 121509 has been described as a highly
specific aldose reductase inhibitor; however,
explaining our observed results strictly on the
basis of inhibition of an increase in polyol syn-
thesis occurring only in the presence of high
glucose is not straight forward.  Aldose reduc-
tase inhibition is known to result in a decreased
accumulation of intracellular sorbitol and in an
increased availability of NADPH [31-34], a co-
factor of NOS. Thus, NOS activity should
increase, remain the same, but not decrease in
the presence of WAY 121509, as is the case in
our experiments. Furthermore, if WAY 121509
were blocking a high glucose-mediated increase
in polyols, then one would expect it to block
responses in high glucose but not in normal
media. In fact, the opposite occurs: WAY
121509 inhibits previously induced NO synthe-
sis in normal media but fails to inhibit the
increased NO synthesis in high glucose media.
An alternative explanation of the effect of WAY
121509 is that this aldose reductase inhibitor is
acting in a non-specific manner [34, 35],
inhibiting either the cytokine-elicited induction
or the activity of the induced NOS, or both.
The complete recovery of NO synthesis after
removal of WAY 121509 might argue that only
the activity of NOS was inhibited, but not its
induction. On the other hand, WAY 121509
was not effective at reducing the activity of the
already induced NOS. Additional experiments
on iNOS enzyme activity, expression of the
iNOS protein, or expression of iNOS mRNA
might help identify the target of WAY 121509.
Even though the inhibition of interleukin-1β-
induced NO by WAY 121509 is rather atypical,
another explanation is that WAY 121509 might
downregulate interleukin-1β-induced NO syn-
thesis indirectly, but still as a consequence of
inhibiting the polyol pathway. Lee et al. [36]
observed in cultures of rat vascular smooth
muscle, that the aldose reductase inhibitor
zopolrestat could antagonize other interleukin-
1β inducible events potentiated by high glucose
concentrations such as prostaglandin produc-
tion and cyclooxygenase (COX-2) expression.
This study suggested that the mechanism by
which high glucose increased interleukin-1β-
induced COX-2 expression involved the indi-
rect activation of protein kinase C through
redox alteration elicited by the polyol pathway.
Redox imbalances caused by the polyol path-
way consists of an increased ratio of
NADP+/NADPH and NADH/NAD+ due to
increased aldose reductase and sorbitol dehy-
drogenase activities, respectively. As mentioned
in the previous paragraph WAY 121509 should
not have decreased interleukin-1β-induced NO
synthesis based solely on the inhibition of the
depletion of the NOS co-factor NADPH.
Nevertheless, the impact of reducing the
NADH/NAD+ ratio downstream due to polyol
inhibition might explain the inhibitory effect of
WAY 121509 on interleukin-1β-induced NO
synthesis. Elevation of the NADH/NAD+ ratio
via sorbitol accumulation results in the novo
synthesis of diacylglycerol (DAG), which is
associated with the activation of protein kinase
C. Evidence supporting PKC activation in
response to high glucose concentrations is well
documented in a variety of cells and tissues
including: retinal vascular endothelial, aortic
endothelial and smooth muscle cells [37-39];
heart [40], isolated glomeruli [41], and in gran-
ulation tissue [42]. It is also well documented in
vascular endothelial [43] and smooth muscle
cells [39] that under hyperglycemic conditions
cytokine-induced activation of the transcrip-
tion factor NFkb increases possibly leading to
up-regulation of interleukin-1β-induced NO
synthesis [43, 44]. Thus, assuming that redox
imbalance only takes place in tissues exposed
to high glucose concentrations, then inhibiting
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WAY 121509 could explain the observed
reduction in interleukin-1β-induced NO syn-
thesis. However, the fact that WAY 121509
inhibited partially interelukin-1β-induced NO
synthesis at physiological levels of glucose sug-
gests that the polyol pathway is active under
this conditions. Indeed, it has been reported
that even under normoglycemic conditions
aldose reductase inhibitors reduce the flux of
glucose via the sorbitol pathway effectively
decreasing both synthesis of polyols and
NADH/NAD+ ratio [45]. 
In conclusion, high glucose up-regulation of
interleukin-1β-induced NO synthesis might be
linked to redox imbalances caused by the poly-
ol pathway. Therefore, increased synthesis of
cytokine-induced NO through high glucose
evoked redox imbalance could be a relevant
pathophysiological mechanism underlying vas-
cular pathogenesis in diabetes.
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